NDA 022555 · Photocure Asa
Cysview Kit
Hexaminolevulinate Hydrochloride · Intravesical
Priority reviewLast checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
May 28, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
22
8 Phase 3, 4 recruiting
FAERS reports
44
9 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 3, 2026.
CYSVIEW is indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) based on a prior cystoscopy Undergoing surveillance cystoscopy for bladder cancer Limitations of Use CYSVIEW is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer [see Warnings and Precautions (5.2) ] . CYSVIEW is an optical imaging agent indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients: With suspected or known lesion(s) on the basis of a prior cystoscopy Undergoing surveillance cystoscopy for bladder cancer Limitations of Use CYSVIEW is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. ( 1 , 5.2 )
Mechanism: Hexaminolevulinate is an ester of the heme precursor, aminolevulinic acid. After bladder instillation, hexaminolevulinate enters the bladder mucosa and is proposed to enter the intracellular space of mucosal cells where it is used as a precursor in the formation of the photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins (PAPs). PpIX and PAPs are reported to accumulate preferentially in neoplastic cells as compared to normal urothelium, partly due to altered enzymatic activity in the neoplastic cells. After excitation with light at wavelengths between 360 nm and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 15, 2018 Supplement 5 · Efficacy · priority review LabelLetter
- May 28, 2010 Original approval · Type 3 - New Dosage Form · priority review LabelReviewSummary Review
1 products under this application
- CYSVIEW KIT · HEXAMINOLEVULINATE HYDROCHLORIDE 100MG/VIAL · FOR SOLUTION, INTRAVESICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Hexaminolevulinate" as an intervention, any sponsor and status, largest first.
- Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence CystoscopyPivotal-lookingCompleted
PhotocureIndustry
NCT00233402 · 789 participants · Start Jan 2005 · Primary completion Jul 2008
Drug: Hexvix · For: Bladder Cancer
Sites: Stanford, California; Gainesville, Florida; Miami, Florida · 25 sites in all
- Photodynamic Diagnosis (PDD) in Flexible CystoscopyPivotal-lookingCompleted
Jørgen Bjerggaard JensenAcademic, hospital or other
NCT02660190 · 696 participants · Start Feb 2016 · Primary completion Dec 2017
Drug: hexaminoavolunate · For: Bladder Cancer; Recurrence; PDD
Sites: Herlev, Denmark; Holstebro, Denmark
- Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)Pivotal-lookingRecruiting
University of Roma La SapienzaAcademic, hospital or other
NCT05962541 · 327 participants (planned) · Start Dec 22, 2025 · Primary completion Dec 2028
Drug: PDD-TURBT with hexaminolevulinate (Hexvix®) · For: Non-muscle-invasive Bladder Cancer; Non-Muscle Invasive Bladder Urothelial Carcinoma; High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Sites: Rome, Italy
- A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance SettingPivotal-lookingCompleted
PhotocureIndustry
NCT02560584 · 304 participants · Start Oct 1, 2015 · Primary completion Apr 5, 2017
Drug: Hexaminolevulinate hydrochloride · For: Bladder Cancer
Sites: Los Angeles, California; Chicago, Illinois; Iowa City, Iowa · 17 sites in all
- Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical NeoplasiaPivotal-lookingCompleted
PhotocureIndustry
NCT01256424 · 262 participants · Start Apr 2011 · Primary completion Sep 2012
Drug: HAL 5% with illumination; HAL 1% with illumination and 2 more · For: Cervical Intraepithelial Neoplasia
Sites: Hanover, Germany; Bergen, Norway
- A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder CancerPivotal-lookingCompleted
PhotocureIndustry
NCT00412971 · 233 participants · Start Apr 2005 · Primary completion Oct 2008
Drug: Hexvix · For: Bladder Cancer
Sites: Frederiksberg, Denmark; Odense, Denmark
- Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light ResectionPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06525571 · 200 participants (planned) · Start Dec 20, 2024 · Primary completion Jan 4, 2027
Drug: Cysview · For: Bladder Cancer
Sites: Washington D.C., District of Columbia; Baltimore, Maryland
Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07944547 · 159 participants (planned) · Start May 26, 2025 · Primary completion Jan 2028
Drug: APL-1702; APL-1702 and 5 more · For: Cervical Intraepithelial Neoplasia Grade 2/3; Human Papillomavirus Infection
Sites: Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9
- medication error4
- pain4
- anaphylactic shock3
- burning sensation3
- hypersensitivity3
- micturition urgency3
- accidental exposure to product2
- cardiac arrest2
- cardio-respiratory arrest2
- hyperhidrosis2
- hypotension2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 7 |
| 2025 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Zhao H, Peng P, Luo Z, et al. · Photodiagnosis Photodyn Ther 2023 · Meta-Analysis, Systematic Review
- Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.
Konecki T, Kutwin P, owicki R, et al. · Photobiomodul Photomed Laser Surg 2019 · Meta-Analysis
- Photodynamic therapy for high-grade squamous intraepithelial lesions: A randomized controlled trial.
Chen F, Hillemanns P, Ruan H, et al. · Med 2025 · Randomized Controlled Trial, Multicenter Study
- Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Stenzl A, Burger M, Fradet Y, et al. · J Urol 2010 · Multicenter Study, Randomized Controlled Trial
- Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis.
Drggoescu PO, Tudorache Ş, Drocaş AI, et al. · Rom J Morphol Embryol 2017 · Randomized Controlled Trial
- [Fluorescence cystoscopy with hexaminolevulinate: our preliminary experience of 184 procedures].
Fanari M, Serra S, Corona A, et al. · Urologia 2011 · Clinical Trial, Comparative Study
Sponsor: Photocure Asa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.